Van Bennekom CM, Kerr SM, Mitchell AA. Oseltamivir exposure in pregnancy and the risk of specific birth defects. Birth Defects Res. 2019 Aug 8
Influenza during pregnancy contributes to maternal morbidity and mortality. Neuraminidase inhibitors, including oseltamivir, are recommended for treating women with influenza during pregnancy.
Data from the Slone Birth Defects Study from 2009 to 2015 were used to investigate associations between oseltamivir and specific birth defects. We classified exposures according to timing in pregnancy and examined 52 and 16 defects with early and potential late pregnancy etiology, respectively; we calculated crude odds ratios (ORs) and 95% confidence intervals (CIs) for defects with three or more exposures.
Among 8,379 cases and 4,190 nonmalformed controls, we identified 79 and 42 oseltamivir exposures, respectively. The majority of defects had no exposures. ORs were elevated for several defects, but the CI excluded the null only for intestinal malrotation (OR: 10.7 [1.8, 45.2]; three exposures).
Largely null findings for specific defects are reassuring. The association with intestinal malrotation, while unstable, warrants further investigation.
- The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain 2 days ago
- Diagnosis of Tamiflu-Resistant Influenza Virus in Human Nasal Fluid and Saliva using Surface-enhanced Raman Scattering 2 days ago
- Comparative Immunogenicity of the 2014-2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children 2 days ago
- Airborne transmission may have played a role in the spread of 2015 highly pathogenic avian influenza outbreaks in the United States 2 days ago
- Use of lentiviral pseudotypes as an alternative to reassortant or Triton X-100-treated wild-type Influenza viruses in the neuraminidase inhibition enzyme-linked lectin assay 2 days ago